PL2262831T4 - Przeciwciała przeciwko properdynie - Google Patents

Przeciwciała przeciwko properdynie

Info

Publication number
PL2262831T4
PL2262831T4 PL08772137T PL08772137T PL2262831T4 PL 2262831 T4 PL2262831 T4 PL 2262831T4 PL 08772137 T PL08772137 T PL 08772137T PL 08772137 T PL08772137 T PL 08772137T PL 2262831 T4 PL2262831 T4 PL 2262831T4
Authority
PL
Poland
Prior art keywords
properdin antibodies
properdin
antibodies
Prior art date
Application number
PL08772137T
Other languages
English (en)
Other versions
PL2262831T3 (pl
Inventor
Rekha Bansal
Original Assignee
Novelmed Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novelmed Therapeutics Inc filed Critical Novelmed Therapeutics Inc
Publication of PL2262831T4 publication Critical patent/PL2262831T4/pl
Publication of PL2262831T3 publication Critical patent/PL2262831T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Surgery (AREA)
  • Psychology (AREA)
PL08772137T 2008-03-03 2008-06-27 Przeciwciała przeciwko properdynie PL2262831T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3312708P 2008-03-03 2008-03-03
PCT/US2008/068530 WO2009110918A1 (en) 2008-03-03 2008-06-27 Anti-properdin antibodies
EP08772137.9A EP2262831B1 (en) 2008-03-03 2008-06-27 Anti-properdin antibodies

Publications (2)

Publication Number Publication Date
PL2262831T4 true PL2262831T4 (pl) 2015-08-31
PL2262831T3 PL2262831T3 (pl) 2015-08-31

Family

ID=41056304

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08772137T PL2262831T3 (pl) 2008-03-03 2008-06-27 Przeciwciała przeciwko properdynie

Country Status (11)

Country Link
US (1) US8435512B2 (pl)
EP (1) EP2262831B1 (pl)
AU (1) AU2008351988B2 (pl)
CY (1) CY1116488T1 (pl)
DK (1) DK2262831T3 (pl)
ES (1) ES2538114T3 (pl)
HR (1) HRP20150434T1 (pl)
PL (1) PL2262831T3 (pl)
PT (1) PT2262831E (pl)
SI (1) SI2262831T1 (pl)
WO (1) WO2009110918A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044111B1 (en) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting complement factor h for treatment of diseases
CA2767105A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
WO2011057158A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
CA2811091C (en) * 2010-03-02 2017-07-25 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin
CN103003302B (zh) * 2010-03-10 2015-09-30 诺沃姆德治疗公司 人源化和嵌合抗-备解素抗体
KR20130080443A (ko) 2010-05-14 2013-07-12 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 개선된 보체 수용체 ２(ｃｒ２) 표적 그룹들
AU2011270959A1 (en) 2010-06-22 2013-01-10 Musc Foundation For Research Development Antibodies to the C3d fragment of complement component 3
BR112013033272A2 (pt) 2011-06-22 2020-11-10 Apellis Pharmaceuticals, Inc. composição farmaceutica compreendendo um inibidor do complemento e um agente anti-th17, e usos dos mesmos
EP2726103B1 (en) * 2011-07-01 2018-09-05 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
SG10201703249PA (en) * 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
EP2797629A4 (en) * 2011-12-28 2015-09-30 Novelmed Therapeutics Inc AGLYCOSYLATED HUMAN ANTIBODY AND FUSION PROTEIN AND USES THEREOF
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
US20150241429A1 (en) * 2012-09-11 2015-08-27 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
CN104870474B (zh) * 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
KR102192596B1 (ko) 2013-08-07 2020-12-18 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
AU2015223056B2 (en) * 2014-02-27 2020-10-01 Allergan, Inc. Complement Factor Bb antibodies
EP3274724A1 (en) * 2015-03-25 2018-01-31 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
ES2772696T3 (es) * 2015-10-30 2020-07-08 Hoffmann La Roche Procedimientos de medición de la actividad del factor D y la potencia de los inhibidores del factor D
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DAMAGE
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
IL267898B2 (en) 2017-01-30 2024-06-01 Alexion Pharma Inc Monovalent antibodies against properdin and their fragments
US11498960B2 (en) 2017-07-11 2022-11-15 Alexion Pharmaceuticals, Inc. Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
MX2022008380A (es) * 2020-01-08 2022-08-04 Zydus Lifesciences Ltd Anticuerpos anti-properdina y preparacion de los mismos.
JP7813771B2 (ja) 2020-08-04 2026-02-13 アボット・ラピッド・ダイアグノスティクス・インターナショナル・アンリミテッド・カンパニー Ｓａｒｓ－ｃｏｖ－２を検出するためのアッセイ
US11981727B2 (en) * 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1007092E (pt) * 1997-08-26 2006-12-29 Amgen Fremont Inc Um processo para inibir a activação do complemento pela via alternativa
WO2003074726A2 (en) * 2002-03-01 2003-09-12 Incyte Corporation Immune response associated proteins
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
JP5707024B2 (ja) * 2005-05-26 2015-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤
US20100263061A1 (en) * 2007-06-11 2010-10-14 The Trustees Of The University Of Pennsylvania Properdin Modulation of Alternative Pathway and Uses Thereof

Also Published As

Publication number Publication date
CY1116488T1 (el) 2017-03-15
PL2262831T3 (pl) 2015-08-31
WO2009110918A1 (en) 2009-09-11
EP2262831A4 (en) 2012-07-25
DK2262831T3 (en) 2015-04-27
EP2262831B1 (en) 2015-01-21
AU2008351988A1 (en) 2009-09-11
EP2262831A1 (en) 2010-12-22
AU2008351988B2 (en) 2013-07-25
US20110008340A1 (en) 2011-01-13
US8435512B2 (en) 2013-05-07
HRP20150434T1 (hr) 2015-06-05
PT2262831E (pt) 2015-05-18
SI2262831T1 (sl) 2015-10-30
ES2538114T3 (es) 2015-06-17

Similar Documents

Publication Publication Date Title
PL2262831T3 (pl) Przeciwciała przeciwko properdynie
ZA201005348B (en) Humanized anti-c5ar antibodies
AP3371A (en) Anti-IGF antibodies
GB0821100D0 (en) Antibodies
ZA201102119B (en) Improved antibody libraies
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
EP2331579A4 (en) MONOCLONAL ANTIBODIES
IL212701A0 (en) Improved anti-cd19 antibodies
GB0909906D0 (en) Antibodies
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
IL217919A0 (en) Humanized anti-cdcp1 antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
ZA201202227B (en) Monoclonal antibodies
IL236236A (en) Antibodies to the fam26f polypeptide
GB0920324D0 (en) Antibodies
GB0905972D0 (en) Antibodies against IL-17BR
ZA201007976B (en) Anti-pirb antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB0818356D0 (en) Antibodies
GB0911770D0 (en) Antibody
GB0823562D0 (en) Antibodies
GB0806230D0 (en) Antibodies
GB0817622D0 (en) Antibody
GB0817621D0 (en) Antibody